Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection

被引:267
作者
Borrow, R
Andrews, N
Goldblatt, D
Miller, E
机构
[1] Withington Hosp, PHLS, Meningococcal Reference Unit, Manchester M20 2LR, Lancs, England
[2] Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Div Immunizat, London NW9 5EQ, England
[3] Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Stat Unit, London NW9 5EQ, England
[4] Inst Child Hlth, Immunobiol Unit, London WC1N 1EII, England
关键词
D O I
10.1128/IAI.69.3.1568-1573.2001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The antibody data supporting the use of meningococcal serogroup C conjugate (MCC) vaccines in the United Kingdom were generated by serum bactericidal assay (SBA) using rabbit complement (rSBA), This may give higher titers than those obtained,vith human complement (hSBA), for which the "gold standard" correlate of protection for meningococcal C disease is a titer of greater than or equal to 4, Comparison of rSBA and hSBA titers in sera from unvaccinated adults with an rSBA titer of greater than or equal to 8 showed that for 93% (27 of 29) the titer was greater than or equal to 4 by hSBA, confirming natural protection. Furthermore, sera from MCC vaccinees showed that an rSBA titer of < 8 or <greater than or equal to> 128 discriminated susceptibility and protection well (85% with rSBA titers of < 8 had hSBA titers of < 4, and 99% with rSBA titers of greater than or equal to 128 had hSBA titers of greater than or equal to 4). However, discrimination was poor in the rSBA titer range 8 to 64, with only 60% having hSBA titers of greater than or equal to 4. In such cases we propose that protection can be assumed if there is a fourfold rise in titer between pre- and postvaccination sera or if there is a characteristic booster response to a polysaccharide challenge dose,vith, if available, evidence of antibody avidity maturation or an hSBA titer of result greater than or equal to 4. Applying these criteria to toddlers, 10 to 40% of whom had titers in the range 8 to 64 after a single dose of MCC vaccine, showed that 94% had a fourfold rise in titer, including 98% of those in the titer range 8 to 64. In addition, of those with titers of < 128 post-MCC vaccination, 90% had titers of <greater than or equal to> 128 after a 10-mug polysaccharide booster dose, compared with only 7% of unprimed age-matched toddlers given a full 50-mug dose. Furthermore, the increase in geometric mean avidity index pre- and postbooster was independent of post-primary MCC titer. These results indicated that the majority of toddlers with an rSBA titer between 8 and 64, and some of those with an hSBA result of < 4, have mounted a protective immune response with the induction of immunological memory.
引用
收藏
页码:1568 / 1573
页数:6
相关论文
共 37 条
  • [1] Streptococcus pneumonia capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory
    Åhman, H
    Käyhty, H
    Lehtonen, H
    Leroy, O
    Froeschle, J
    Eskola, J
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (03) : 211 - 216
  • [2] SAFETY AND IMMUNOGENICITY OF MENINGOCOCCAL A-POLYSACCHARIDE AND C-POLYSACCHARIDE CONJUGATE VACCINE IN ADULTS
    ANDERSON, EL
    BOWERS, T
    MINK, CM
    KENNEDY, DJ
    BELSHE, RB
    HARAKEH, H
    PAIS, L
    HOLDER, P
    CARLONE, GM
    [J]. INFECTION AND IMMUNITY, 1994, 62 (08) : 3391 - 3395
  • [3] Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines
    Anttila, M
    Eskola, J
    Åhman, H
    Käyhty, H
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (06) : 1614 - 1621
  • [4] PREVENTION OF MENINGOCOCCAL DISEASE BY GROUP-C POLYSACCHARIDE VACCINE
    ARTENSTEIN, MS
    GOLD, R
    ZIMMERLY, JG
    WYLE, FA
    SCHNEIDER, H
    HARKINS, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1970, 282 (08) : 417 - +
  • [5] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [6] EFFICACY OF HAEMOPHILUS-INFLUENZAE TYPE-B CONJUGATE VACCINE PRP-T
    BOOY, R
    HODGSON, S
    CARPENTER, L
    MAYONWHITE, RT
    SLACK, MPE
    MACFARLANE, JA
    HAWORTH, EA
    KIDDLE, M
    SHRIBMAN, S
    ROBERTS, JSC
    MOXON, ER
    [J]. LANCET, 1994, 344 (8919) : 362 - 366
  • [7] Borrow R, 2000, FEMS IMMUNOL MED MIC, V28, P79, DOI 10.1111/j.1574-695X.2000.tb01460.x
  • [8] Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine
    Borrow, R
    Fox, AJ
    Richmond, PC
    Clark, S
    Sadler, F
    Findlow, J
    Morris, R
    Begg, NT
    Cartwright, KAV
    [J]. EPIDEMIOLOGY AND INFECTION, 2000, 124 (03) : 427 - 432
  • [9] Brandtzaeg P., 1995, Meningococcal disease, P71
  • [10] Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger
    Campagne, G
    Garba, A
    Fabre, P
    Schuchat, A
    Ryall, R
    Boulanger, D
    Bybel, M
    Carlone, G
    Briantais, P
    Ivanoff, B
    Xerri, B
    Chippaux, JP
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (02) : 144 - 150